CRISPR-based epigenome and genome editing reveal novel roles for PLEC in cartilage biology, mechanobiology, and response to inflammation

Osteoarthritis is the most common form of arthritis, a condition where the smooth, protective cartilage that cushions the ends of bones wears away, leading to pain and stiffness. While age and injury are well-known triggers, scientists have long suspected that our genes play a massive role in who develops the disease and how quickly it progresses. Researchers have identified specific spots in our DNA, called single-nucleotide polymorphisms, that are linked to a higher risk of osteoarthritis. However, most of these risky spots do not contain the actual instructions for making proteins; instead, they sit in the non-coding regions of the genome. Think of these regions as the volume knobs and dimmer switches of a radio; they do not play the music themselves, but they control how loudly or quietly the music plays. In the case of osteoarthritis, these genetic switches likely work by turning the activity of certain genes up or down through a process called DNA methylation, which acts like a chemical tag that can silence a gene. Understanding exactly how these silent switches control the health of our cartilage is crucial for finding new ways to treat the disease.

A team of researchers at Washington University School of Medicine and several international institutions has taken a significant step toward unlocking this mystery by focusing on a specific genetic risk factor known as rs11780978. This genetic variant is located near a gene called PLEC, which produces a large protein called plectin. Plectin acts as a structural glue inside cells, holding the internal skeleton together and helping cells sense and respond to physical forces. The researchers wanted to know if this genetic risk factor changes the way plectin is made in cartilage cells, and if having less plectin makes those cells more vulnerable to the wear and tear of daily life and inflammation. To find out, they built a sophisticated laboratory system that allowed them to edit the genetic code and the chemical tags on the DNA of human cartilage cells, effectively creating a controlled environment to test how these changes affect the cells' ability to build and maintain healthy tissue.

The scientists began by confirming that the genetic risk factor they were studying was indeed linked to specific chemical tags on the DNA in human cartilage samples taken from patients. They identified several new locations where the genetic code influenced these tags, expanding the map of how this risk factor might work. Using a precise tool that acts like a molecular eraser, they removed the chemical tags from these specific spots in the DNA of laboratory-grown cartilage cells. They observed that when they removed these tags, the activity of the plectin gene dropped significantly. This provided strong evidence that the genetic risk factor works by altering the chemical environment of the DNA, which in turn reduces the amount of plectin the cell produces. Having established this link, the team then moved to the next phase: creating a cell line that naturally lacked plectin to see what would happen when the cells tried to grow and function without it.

To study the effects of missing plectin, the researchers used a special type of human stem cell that can be coaxed into becoming cartilage cells. They used a gene-editing technique to delete a small piece of the plectin gene, creating a version of the cells that could not make the full protein. They verified that these edited cells had significantly lower levels of plectin at the DNA, RNA, and protein levels, and that this deficiency persisted even as the cells grew and matured into cartilage-like structures. When these plectin-deficient cells were allowed to form cartilage in a dish, they showed a subtle but important change in their behavior. While they were still able to build cartilage, they produced less of the key building blocks, such as type II collagen and aggrecan, which are essential for the tissue's strength and ability to absorb shock. Interestingly, the cells did not show signs of becoming scar tissue or aging prematurely, suggesting that the lack of plectin specifically weakened the cartilage's ability to build itself up rather than causing it to break down faster.

The researchers then subjected these cells to the kinds of stress they would face inside a human body. They exposed the cartilage to inflammatory signals, similar to what happens during a flare-up of arthritis, and to mechanical pressure, mimicking the force of walking or running. When the cells were hit with inflammation, they reacted by reducing their production of healthy cartilage components, a response seen in both the normal and the plectin-deficient cells. However, the plectin-deficient cells showed a slightly different pattern in their genetic response to inflammation, producing less of a specific inflammatory signal called IL-6. This suggests that while the cells still suffered from the inflammation, the way they communicated that stress to the rest of the body was altered.

Perhaps the most revealing part of the study came when the researchers combined mechanical pressure with inflammation, creating a "mechano-inflammatory" environment that closely mimics the conditions inside an arthritic joint. They analyzed the genetic activity of the cells under these conditions and found that the absence of plectin changed how the cells responded to the physical load. The plectin-deficient cells turned on a different set of genes compared to the normal cells. Some of these genes were related to how the cell's internal skeleton is organized, while others were linked to long strands of genetic material that regulate how other genes work. One of the most notable findings was that the plectin-deficient cells failed to properly activate a gene called H19, which is known to help cartilage repair itself. Without this gene being turned on correctly, the cells might struggle to repair the damage caused by daily movement, especially when that movement is accompanied by inflammation.

The study also looked at whether the lack of plectin changed the physical stiffness of the cells or their ability to sense force. Using a highly sensitive microscope probe, the researchers pressed on individual cells to see how much they deformed and how they reacted with calcium signals. Surprisingly, the cells without plectin were just as stiff and just as responsive to the physical push as the normal cells. This indicates that the problem is not that the cells cannot feel the force or that they are physically weaker in a simple sense. Instead, the issue lies in how the cells translate that physical feeling into a genetic response. The internal skeleton, which plectin helps to hold together, seems to be critical for sending the right messages to the cell's nucleus to tell it to build more cartilage when it is under pressure.

By connecting a specific genetic risk factor to a chemical change in the DNA, and then linking that chemical change to a deficiency in a structural protein, the researchers have drawn a clear line from a tiny variation in our genetic code to the health of our joints. They showed that having a genetic risk factor for osteoarthritis can lead to lower levels of plectin, which in turn makes cartilage cells less effective at building and repairing themselves when they are under stress. This work does not offer an immediate cure, but it provides a detailed map of how a genetic vulnerability might lead to disease. It highlights plectin as a key player in the complex conversation between our genes, our environment, and our joints, suggesting that future treatments might need to focus on helping these cells overcome their structural weaknesses to better withstand the daily demands of life.